10x Genomics AI Stock Analysis
10x Genomics (0A88) AI Stock Analysis
10x Genomics
(LSE:0A88)
No summary available
10x Genomics (0A88) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $6.84B
- Dividend Yield
- ―
- Average Volume (3M)
- 5,176
- Price to Earnings (P/E)
- -107.7
- Beta (1Y)
- 1.19
- Revenue Growth
- -3.62%
- EPS Growth
- 16.67%
- Country
- UK
- Employees
- 1,178
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
10x Genomics Business Overview & Revenue Model
Company Description
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated inst...
10x Genomics Earnings Call Summary
The call was strongly positive overall. Management reported raised revenue guidance, strong consumables performance, growing Atera demand, broad customer interest, expanding AI-related opportunities, improving cash generation and progress across product and clinical initiatives. The main negatives were modest 1% total revenue growth, substantial instrument revenue declines, near-term gross margin compression from the Atera ramp, Apex-related top-line pressure and production and installation constraints.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised its 2026 revenue outlook to the range of $625 million to $635 million, up from $610 million to $630 million, representing 4% to 6% growth over the full year 2025 excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025; it now expects to ship approximately 50 Atera instruments by year-end, up from the previous expectation of approximately 40, and said 50 a quarter between those constraints is about the right number going into next year. Gross margins are expected to be in the low to mid-60s for Q4, while 2027 margins will most likely come in lower than where they are because it will be an instrument heavy year and consumables will start to ramp during the course of the year; Spatial consumables in Q4 are expected to still be double digits for sure, with a full quarter of Atera consumables shipments.
10x Genomics Risk Analysis
10x Genomics disclosed 10 risk factors in its most recent earnings report. 10x Genomics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New Risks10x Genomics Peers Comparison
Overall Rating
TECH74Outperform
ADPT64Neutral
TWST52Neutral
MRVI48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | $11.41B | 66.08 | 8.22% | 0.55% | 0.94% | 122.38% | |
| 64Neutral | $4.61B | -62.93 | -37.40% | ― | 17.91% | 16.01% | |
| 52Neutral | $7.64B | -53.21 | -23.20% | ― | 22.00% | -60.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $1.89B | -16.31 | -31.86% | ― | 10.77% | 46.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A88 | 10X Genomics | 55.01 | 39.21 | 248.21% | |
| TECH | Bio-Techne | 72.63 | 15.13 | 26.32% | |
| TWST | Twist Bioscience | 112.00 | 86.55 | 340.08% | |
| ADPT | Adaptive Biotechnologies | 28.49 | 13.34 | 88.05% | |
| MRVI | Maravai Lifesciences Holdings, Inc. | 7.28 | 3.78 | 108.00% | |
| ALMR | Alamar Biosciences, Inc. | 30.64 | 8.64 | 39.27% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
